PL3628670T3 - Postać soli dla inhibicji ezh2 - Google Patents
Postać soli dla inhibicji ezh2Info
- Publication number
- PL3628670T3 PL3628670T3 PL19180479.8T PL19180479T PL3628670T3 PL 3628670 T3 PL3628670 T3 PL 3628670T3 PL 19180479 T PL19180479 T PL 19180479T PL 3628670 T3 PL3628670 T3 PL 3628670T3
- Authority
- PL
- Poland
- Prior art keywords
- salt form
- ezh2 inhibition
- ezh2
- inhibition
- salt
- Prior art date
Links
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3628670T3 true PL3628670T3 (pl) | 2023-02-20 |
Family
ID=49328166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16191716T PL3184523T3 (pl) | 2012-04-13 | 2013-04-11 | Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego |
| PL19180479.8T PL3628670T3 (pl) | 2012-04-13 | 2013-04-11 | Postać soli dla inhibicji ezh2 |
| PL13774979T PL2836491T3 (pl) | 2012-04-13 | 2013-04-11 | Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16191716T PL3184523T3 (pl) | 2012-04-13 | 2013-04-11 | Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13774979T PL2836491T3 (pl) | 2012-04-13 | 2013-04-11 | Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2 |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9394283B2 (pl) |
| EP (4) | EP3184523B1 (pl) |
| JP (3) | JP6255382B2 (pl) |
| KR (4) | KR20250005505A (pl) |
| CN (2) | CN104603130B (pl) |
| AU (2) | AU2013245878B2 (pl) |
| BR (1) | BR112014025508B1 (pl) |
| CA (1) | CA2870005C (pl) |
| CY (2) | CY1119383T1 (pl) |
| DK (3) | DK3628670T3 (pl) |
| ES (3) | ES2745016T3 (pl) |
| HR (2) | HRP20170295T1 (pl) |
| HU (3) | HUE031976T2 (pl) |
| IL (4) | IL296199B2 (pl) |
| IN (1) | IN2014DN09068A (pl) |
| LT (2) | LT3184523T (pl) |
| MX (2) | MX384641B (pl) |
| NZ (1) | NZ700761A (pl) |
| PL (3) | PL3184523T3 (pl) |
| PT (3) | PT2836491T (pl) |
| RS (2) | RS55690B1 (pl) |
| RU (1) | RU2658911C2 (pl) |
| SG (3) | SG10201608577RA (pl) |
| SI (2) | SI2836491T1 (pl) |
| SM (2) | SMT201700132T1 (pl) |
| WO (1) | WO2013155317A1 (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP6340361B2 (ja) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | がんを処置するための組合せ治療 |
| IL296199B2 (en) | 2012-04-13 | 2024-12-01 | Eisai R&D Man Co Ltd | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| AU2013331380B2 (en) * | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9505745B2 (en) | 2013-04-30 | 2016-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| ES2640386T3 (es) | 2013-07-10 | 2017-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Potenciador de inhibidores del homólogo Zeste 2 |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
| US20160228447A1 (en) * | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| KR20210117347A (ko) | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| LT3157527T (lt) | 2014-06-17 | 2023-07-25 | Epizyme, Inc. | Ezh2 inhibitoriai, skirti limfomos gydymui |
| CN106687463B (zh) | 2014-06-20 | 2019-04-09 | 星座制药公司 | 一种乙酰胺类化合物的晶型 |
| MX394629B (es) | 2014-10-16 | 2025-03-24 | Epizyme Inc | Método para tratar el cáncer. |
| EP4272742A1 (en) | 2014-11-17 | 2023-11-08 | Epizyme Inc | Epz-6438 for use in a method for treating cancer |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| CA2988816A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| CA3039059A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| WO2018137639A1 (zh) * | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技（上海）有限公司 | 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| MD4003532T2 (ro) | 2019-07-24 | 2025-01-31 | Constellation Pharmaceuticals Inc | Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| BR112022012258A2 (pt) * | 2019-12-20 | 2022-08-30 | Epizyme Inc | Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| ATE180468T1 (de) | 1993-12-27 | 1999-06-15 | Eisai Co Ltd | Anthranilsäure derivate |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| CN1332722A (zh) | 1998-09-30 | 2002-01-23 | 宝洁公司 | 2－取代的酮酰胺 |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE60139506D1 (de) | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US20050101590A1 (en) | 2002-02-19 | 2005-05-12 | Kiyoshi Yasui | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| RU2006138036A (ru) | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
| WO2005118796A2 (en) | 2004-06-01 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ATE494548T1 (de) | 2005-06-02 | 2011-01-15 | Univ North Carolina | Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| PE20110285A1 (es) | 2005-10-19 | 2011-06-04 | Gruenenthal Chemie | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 |
| EP1951672B1 (en) | 2005-10-21 | 2011-05-25 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| JP5078901B2 (ja) | 2005-10-28 | 2012-11-21 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ＪｍｊＣドメインを含むタンパク質デメチラーゼ |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| WO2008073138A2 (en) | 2006-05-15 | 2008-06-19 | Irm Llc | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors |
| CA2652634A1 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certain substituted quinolones, compositions, and uses thereof |
| WO2008108825A2 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| EP2215049B1 (en) | 2007-10-31 | 2019-06-12 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2010017355A2 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| EA023788B1 (ru) * | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| KR102587175B1 (ko) | 2012-03-12 | 2023-10-06 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| JP6340361B2 (ja) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | がんを処置するための組合せ治療 |
| IL296199B2 (en) * | 2012-04-13 | 2024-12-01 | Eisai R&D Man Co Ltd | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
-
2013
- 2013-04-11 IL IL296199A patent/IL296199B2/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 MX MX2019000449A patent/MX384641B/es unknown
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 KR KR1020247041285A patent/KR20250005505A/ko active Pending
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active Active
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active Active
- 2013-04-11 KR KR1020227029511A patent/KR102744039B1/ko active Active
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en not_active Ceased
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 SM SM20170132T patent/SMT201700132T1/it unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 SM SM20190501T patent/SMT201900501T1/it unknown
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US12251386B2/en active Active
-
2025
- 2025-02-13 US US19/053,007 patent/US20250268905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3628670T3 (pl) | Postać soli dla inhibicji ezh2 | |
| IL244787A0 (en) | Hydrochloride salt form for ezh2 inhibition | |
| ZA201503041B (en) | Gdf-8 inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| ZA201401268B (en) | Noribogaine salt ansolvates | |
| HUE048834T2 (hu) | Kináz inhibitorok | |
| ZA201404156B (en) | Kinase inhibitors | |
| GB201216017D0 (en) | Inhibitor compounds | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| IL229028A0 (en) | Kinase inhibitors | |
| ZA201407904B (en) | Nampt inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| ZA201404157B (en) | Kinase inhibitors | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2744788A4 (en) | BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS | |
| IL239281A0 (en) | Dihydrochloride salt of cubicistat | |
| GB201219306D0 (en) | Nampt inhibitors |